The Response Evaluation Criteria in Solid Tumors (RECIST) guidelines are likely not sensitive enough for tumor assessment and can lead to inconsistent results. Research by Dr. Christiane Kuhl showed that when a group of five readers, three of which were radiologists, reviewed metastatic tumors on patient’s CT scans based on the RECIST guidelines, the readers selected the same group of representative tumors only 40.5% of the time and chose different tumors 59.5% of the time, despite using the same RECIST-based criteria. This lead to differing treatment recommendations for many patients.
Read the full article here.
HealthMyne’s Therapy Response module walks the reader through a step-by-step process for identifying and measuring lesions for multiple response protocols including RECIST. Additionally, automatic propagation to subsequent image sets ensures the correct lesions are measured and compared no matter who does the follow-up read.